Improved insulin sensitivity due to Ozempic can result in a modification in the levels of estrogen and progesterone
Patients should undergo TSH and free thyroid hormone testing every 68 weeks during the first months of semaglutide therapy, then every 3 months as treatment stabilizes, to detect any shifts requiring antithyroid or replacement hormone adjustment
Initially, semaglutide was first approved in 2017 by the US Food and Drug Administration (FDA) as a diabetes drug under the brand name Ozempic
Clinical trials of GLP-1 agonists have consistently shown that these medications can help reduce hunger and prevent overeating, leading to weight loss
Nevertheless, standard drug tests rarely detect peptides, reserving such analysis for specialized doping scenarios
More clinically relevant, however, are the downstream effects of rapid weight loss and altered metabolic signaling